Xeljanz Warnings on Shingles Updated by FDA Save

The MedWatch June 2015 safety labeling changes were published yesterday, and updated the warnings for Xeljanz (tofacitinib). "The risk of herpes zoster is increased in patients treated with Xeljanz and appears to be higher in patients treated with Xeljanz in Japan."

Also, when Xeljanz is used in diabetics, it should be noted that "as there is a higher incidence of infection in diabetic population in general, caution should be used when treating patients with diabetes."